Why the study?
How do NOAC-specific reversal agents fit into the framework of managing NOAC-related bleeding in patients with atrial fibrillation?
How do NOAC-specific reversal agents fit into the framework of managing NOAC-related bleeding in patients with atrial fibrillation?
This review provides a framework for utilizing newly approved and emerging NOAC-specific reversal agents to manage bleeding complications in patients on oral anticoagulants.
Answers are grounded in this paper and cite their sources.
May support NOAC reversal integration into AF bleeding protocols; leaves open need for prospective validation.
Clinical trials in patients with atrial fibrillation have demonstrated that non-vitamin K antagonist oral anticoagulants [novel oral anticoagulants (NOACs)] are markedly safer than warfarin with respect to serious bleeding-especially intracranial hemorrhage, the most feared and devastating complication of anticoagulant therapy. Registries and large retrospective database studies have confirmed these findings. Additionally, patients who do experience bleeding while taking NOACs have similar or better outcomes than do patients on warfarin. However, despite these data, many physicians and patients have been reluctant to embrace NOAC use due to their perception that they are not able to effectively manage patients who present with bleeding, particularly without a specific reversal agent or antidote on-hand. With the approval of the first NOAC-specific reversal agent and with others in late-stage clinical development, it is helpful to review how these agents may fit in the framework of managing NOAC-related bleeding.
No takes yet. Share an insight, caveat, or question.
Christian T. Ruff (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: